L H Lehmann1,2,3, S Fröhling4,5. 1. Innere Medizin III, Abteilung für Kardiologie, Pneumologie und Angiologie, Sektion Kardio-Onkologie, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Deutschland. Lorenz.Lehmann@med.uni-heidelberg.de. 2. Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), Standort Heidelberg/Mannheim, Heidelberg, Deutschland. Lorenz.Lehmann@med.uni-heidelberg.de. 3. Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Deutschland. Lorenz.Lehmann@med.uni-heidelberg.de. 4. Abteilung für Translationale Medizinische Onkologie, Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg und DKFZ, Heidelberg, Deutschland. 5. Deutsches Konsortium für Translationale Krebsforschung (DKTK), Heidelberg, Deutschland.
Abstract
BACKGROUND: Oncological therapies show a number of undesired adverse effects on the cardiovascular system. In particular, the side effects of recently established oncological therapies are incompletely understood and clinical data are lacking in the interpretation of novel cardiac complications. OBJECTIVE: This article provides a short overview of the mechanisms of cardiac side effects of certain oncological therapies. MATERIAL AND METHODS: The review is mainly based on data from preclinical studies. RESULTS: Numerous toxic side effects have already been described and investigated in preclinical models. For certain groups of drugs (e.g. anthracyclines, tyrosine kinase inhibitors and immune checkpoint inhibitors) the underlying molecular mechanisms are still not fully understood. CONCLUSION: An improved understanding of the molecular mechanism involved in cardiotoxicity might help improve the quality of clinical decisions. Additionally, it will provide new insights into the pathophysiology of cardiac diseases. The aim is to use the results of translational research and to clinically implement them in suitable cardio-oncology units.
BACKGROUND: Oncological therapies show a number of undesired adverse effects on the cardiovascular system. In particular, the side effects of recently established oncological therapies are incompletely understood and clinical data are lacking in the interpretation of novel cardiac complications. OBJECTIVE: This article provides a short overview of the mechanisms of cardiac side effects of certain oncological therapies. MATERIAL AND METHODS: The review is mainly based on data from preclinical studies. RESULTS: Numerous toxic side effects have already been described and investigated in preclinical models. For certain groups of drugs (e.g. anthracyclines, tyrosine kinase inhibitors and immune checkpoint inhibitors) the underlying molecular mechanisms are still not fully understood. CONCLUSION: An improved understanding of the molecular mechanism involved in cardiotoxicity might help improve the quality of clinical decisions. Additionally, it will provide new insights into the pathophysiology of cardiac diseases. The aim is to use the results of translational research and to clinically implement them in suitable cardio-oncology units.
Authors: Mazen W Karaman; Sanna Herrgard; Daniel K Treiber; Paul Gallant; Corey E Atteridge; Brian T Campbell; Katrina W Chan; Pietro Ciceri; Mindy I Davis; Philip T Edeen; Raffaella Faraoni; Mark Floyd; Jeremy P Hunt; Daniel J Lockhart; Zdravko V Milanov; Michael J Morrison; Gabriel Pallares; Hitesh K Patel; Stephanie Pritchard; Lisa M Wodicka; Patrick P Zarrinkar Journal: Nat Biotechnol Date: 2008-01 Impact factor: 54.908
Authors: Jie Li; Ping-Yuan Wang; Nathaniel A Long; Jie Zhuang; Danielle A Springer; Jizhong Zou; Yongshun Lin; Christopher K E Bleck; Ji-Hoon Park; Ju-Gyeong Kang; Paul M Hwang Journal: Proc Natl Acad Sci U S A Date: 2019-09-05 Impact factor: 11.205
Authors: Robert F Cornell; Bonnie Ky; Brendan M Weiss; Cherie N Dahm; Deepak K Gupta; Liping Du; Joseph R Carver; Adam D Cohen; Brian G Engelhardt; Alfred L Garfall; Stacey A Goodman; Shelton Lacy Harrell; Adetola A Kassim; Trafina Jadhav; Madan Jagasia; Javid Moslehi; Rupal O'Quinn; Michael R Savona; David Slosky; Amanda Smith; Edward A Stadtmauer; Dan T Vogl; Adam Waxman; Daniel Lenihan Journal: J Clin Oncol Date: 2019-06-12 Impact factor: 44.544
Authors: Sui Zhang; Xiaobing Liu; Tasneem Bawa-Khalfe; Long-Sheng Lu; Yi Lisa Lyu; Leroy F Liu; Edward T H Yeh Journal: Nat Med Date: 2012-10-28 Impact factor: 53.440
Authors: Henrike Tscheschner; Eric Meinhardt; Philipp Schlegel; Andreas Jungmann; Lorenz H Lehmann; Oliver J Müller; Patrick Most; Hugo A Katus; Philip W Raake Journal: PLoS One Date: 2019-04-29 Impact factor: 3.240
Authors: Dulguun Amgalan; Thomas P Garner; Ryan Pekson; Xiaotong F Jia; Mounica Yanamandala; Victor Paulino; Felix G Liang; J Jose Corbalan; Jaehoon Lee; Yun Chen; George S Karagiannis; Luis Rivera Sanchez; Huizhi Liang; Swathi-Rao Narayanagari; Kelly Mitchell; Andrea Lopez; Victoria Margulets; Marco Scarlata; Gaetano Santulli; Aarti Asnani; Randall T Peterson; Rachel B Hazan; John S Condeelis; Maja H Oktay; Ulrich Steidl; Lorrie A Kirshenbaum; Evripidis Gavathiotis; Richard N Kitsis Journal: Nat Cancer Date: 2020-03-02